Epoetin beta for the treatment of chemotherapy-induced anemia: an update.
about
Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) - non-interventional study.Stability of erythropoietin repackaging in polypropylene syringes for clinical use.Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer.
P2860
Epoetin beta for the treatment of chemotherapy-induced anemia: an update.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Epoetin beta for the treatment of chemotherapy-induced anemia: an update.
@ast
Epoetin beta for the treatment of chemotherapy-induced anemia: an update.
@en
type
label
Epoetin beta for the treatment of chemotherapy-induced anemia: an update.
@ast
Epoetin beta for the treatment of chemotherapy-induced anemia: an update.
@en
prefLabel
Epoetin beta for the treatment of chemotherapy-induced anemia: an update.
@ast
Epoetin beta for the treatment of chemotherapy-induced anemia: an update.
@en
P2093
P2860
P356
P1476
Epoetin beta for the treatment of chemotherapy-induced anemia: an update.
@en
P2093
Clara Ricci
Colin Gerard Egan
Luca Galli
P2860
P304
P356
10.2147/OTT.S77497
P407
P577
2015-03-05T00:00:00Z